Gastrointestinal prokinetic therapy: Acetylcholinesterase inhibitors

Jean A. Hall, Robert J. Washabau

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

In cats and dogs, motility disorders of the esophagus, stomach, small intestine, and colon are common. Traditionally, these conditions have been treated primarily by dietary management and surgical intervention. In recent years, gastrointestinal prokinetic therapy has become increasingly important in the clinical management of patients with these disorders. In this five-part Continuing Education Series, the first four articles divide gastrointestinal prokinetic drugs into four groups - for each group, the mechanisms of action, site of activity, and indications are discussed. The first part provided information concerning the dopaminergic antagonist drugs. The second part considered motilin-like drugs, particularly erythromycin and the other macrolides. The third article in the series discussed serotonergic drugs, especially cisapride. This part considers the acetylcholinesterase inhibitors or parasympathetic potentiating drugs. Ranitidine and nizatidine are competitive, reversible H 2-receptor antagonists with gastric antisecretory properties. Both agents may have clinical applications in gastrointestinal prokinetic therapy that are not associated with cimetidine or famotidine. The final article of the series will discuss the diagnosis and treatment of esophageal, gastric, intestinal, and colonic motility disorders.

Original languageEnglish (US)
Pages (from-to)615-620
Number of pages6
JournalCompendium on Continuing Education for the Practicing Veterinarian
Volume19
Issue number5
StatePublished - May 1 1997

Fingerprint

Cholinesterase Inhibitors
acetylcholinesterase
Stomach
drug
drugs
therapeutics
Nizatidine
stomach
Motilin
Cisapride
Famotidine
Serotonin Agents
Gastrointestinal Agents
Dopamine Agents
Ranitidine
Gastrointestinal Motility
Dopamine Antagonists
Cimetidine
Continuing Education
Macrolides

Cite this

Gastrointestinal prokinetic therapy : Acetylcholinesterase inhibitors. / Hall, Jean A.; Washabau, Robert J.

In: Compendium on Continuing Education for the Practicing Veterinarian, Vol. 19, No. 5, 01.05.1997, p. 615-620.

Research output: Contribution to journalReview article

@article{3d9cf494fa57418e819c5373d770ba47,
title = "Gastrointestinal prokinetic therapy: Acetylcholinesterase inhibitors",
abstract = "In cats and dogs, motility disorders of the esophagus, stomach, small intestine, and colon are common. Traditionally, these conditions have been treated primarily by dietary management and surgical intervention. In recent years, gastrointestinal prokinetic therapy has become increasingly important in the clinical management of patients with these disorders. In this five-part Continuing Education Series, the first four articles divide gastrointestinal prokinetic drugs into four groups - for each group, the mechanisms of action, site of activity, and indications are discussed. The first part provided information concerning the dopaminergic antagonist drugs. The second part considered motilin-like drugs, particularly erythromycin and the other macrolides. The third article in the series discussed serotonergic drugs, especially cisapride. This part considers the acetylcholinesterase inhibitors or parasympathetic potentiating drugs. Ranitidine and nizatidine are competitive, reversible H 2-receptor antagonists with gastric antisecretory properties. Both agents may have clinical applications in gastrointestinal prokinetic therapy that are not associated with cimetidine or famotidine. The final article of the series will discuss the diagnosis and treatment of esophageal, gastric, intestinal, and colonic motility disorders.",
author = "Hall, {Jean A.} and Washabau, {Robert J.}",
year = "1997",
month = "5",
day = "1",
language = "English (US)",
volume = "19",
pages = "615--620",
journal = "Compendium on Continuing Education for the Practicing Veterinarian",
issn = "0193-1903",
publisher = "Veterinary Learning Systems",
number = "5",

}

TY - JOUR

T1 - Gastrointestinal prokinetic therapy

T2 - Acetylcholinesterase inhibitors

AU - Hall, Jean A.

AU - Washabau, Robert J.

PY - 1997/5/1

Y1 - 1997/5/1

N2 - In cats and dogs, motility disorders of the esophagus, stomach, small intestine, and colon are common. Traditionally, these conditions have been treated primarily by dietary management and surgical intervention. In recent years, gastrointestinal prokinetic therapy has become increasingly important in the clinical management of patients with these disorders. In this five-part Continuing Education Series, the first four articles divide gastrointestinal prokinetic drugs into four groups - for each group, the mechanisms of action, site of activity, and indications are discussed. The first part provided information concerning the dopaminergic antagonist drugs. The second part considered motilin-like drugs, particularly erythromycin and the other macrolides. The third article in the series discussed serotonergic drugs, especially cisapride. This part considers the acetylcholinesterase inhibitors or parasympathetic potentiating drugs. Ranitidine and nizatidine are competitive, reversible H 2-receptor antagonists with gastric antisecretory properties. Both agents may have clinical applications in gastrointestinal prokinetic therapy that are not associated with cimetidine or famotidine. The final article of the series will discuss the diagnosis and treatment of esophageal, gastric, intestinal, and colonic motility disorders.

AB - In cats and dogs, motility disorders of the esophagus, stomach, small intestine, and colon are common. Traditionally, these conditions have been treated primarily by dietary management and surgical intervention. In recent years, gastrointestinal prokinetic therapy has become increasingly important in the clinical management of patients with these disorders. In this five-part Continuing Education Series, the first four articles divide gastrointestinal prokinetic drugs into four groups - for each group, the mechanisms of action, site of activity, and indications are discussed. The first part provided information concerning the dopaminergic antagonist drugs. The second part considered motilin-like drugs, particularly erythromycin and the other macrolides. The third article in the series discussed serotonergic drugs, especially cisapride. This part considers the acetylcholinesterase inhibitors or parasympathetic potentiating drugs. Ranitidine and nizatidine are competitive, reversible H 2-receptor antagonists with gastric antisecretory properties. Both agents may have clinical applications in gastrointestinal prokinetic therapy that are not associated with cimetidine or famotidine. The final article of the series will discuss the diagnosis and treatment of esophageal, gastric, intestinal, and colonic motility disorders.

UR - http://www.scopus.com/inward/record.url?scp=0141877420&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141877420&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:0141877420

VL - 19

SP - 615

EP - 620

JO - Compendium on Continuing Education for the Practicing Veterinarian

JF - Compendium on Continuing Education for the Practicing Veterinarian

SN - 0193-1903

IS - 5

ER -